Injectable GLP-1 analogs are effective tools in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. However, the complexity of manufacturing these peptide analogs, as well as the need for daily injections, have limited their broad use.

XW003 is a novel, long-lasting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing and once weekly dosing. XW003 has been shown to be safe and well tolerated in a Phase 1 clinical study. Phase 2 studies are underway to study XW003 as a potential treatment for type 2 diabetes, obesity, and NAFLD/NASH.

XW004 is an oral formulation of the GLP-1 peptide analog XW003. To enable oral bioavailability, the peptide is co-formulated with an oral absorption enhancer agent that prevents drug deactivation in the intestinal tract and increases intestinal absorption. This formulation allows for daily oral dosing.

With the improved ease-of-use of a daily pill, XW004 offers the potential of a GLP-1 analog therapy to a broader patient population, as well as facilitates combinations with other oral drugs to further enhance treatment efficacy. XW004 will enter clinical trials in late 2021.

XW014 is a small molecule GLP-1 receptor agonist with the potential to be dosed orally once a day. Compared with GLP-1 peptide analogs, this small molecule agonist is easier to manufacture and formulate for oral dosing.

As a small molecule, XW014 has the potential to be co-formulated with other oral drugs of complementary mechanisms to generate more effective combination treatments for obesity, type 2 diabetes, and NASH. XW014 is slated to enter clinical trials in the first half of 2022.

In combination with GLP-1 analogs, injectable GIP receptor agonists have demonstrated improved glycemic control and metabolic health, as well as more profound weight loss, in clinical trials. 

XW017 is a novel, long-lasting GIP peptide analog optimized for biological activity and in vivo stability. It has the potential to be co-formulated with GLP-1 analogs to generate more effective combination treatments for obesity, type 2 diabetes, and NASH. XW017 is anticipated to enter clinical trials in the first half of 2023.

XW001 is an inhaled formulation of interferon-lambda (IFN-l) being developed for treatment of viral respiratory diseases.

XW001 has demonstrated broad-spectrum antiviral activity against various respiratory viruses in preclinical models, including RSV, SARS-CoV-2 (the causative agent of COVID-19), and influenza viruses.